COMMUNIQUÉS West-GlobeNewswire

MedTainer’s Record-Setting Pace Continues, Plans for Expansion Proceed
01/03/2019
CORONA, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- MedTainer Inc. (MDTR-OTCMARKETS) announced today that orders for its signature product, the MedTainer™, have continued to rise and the company has recorded the biggest [...]
Yield Growth’s Urban Juve Takes a Fresh Approach to Skincare-- CFN Media
01/03/2019
SEATTLE, March 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of [...]
Spero Therapeutics to Present at March Investor Conferences
01/03/2019
CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
01/03/2019
CHMP recommends approval of Dupixent ® (dupilumab) for asthma indication PARIS and TARRYTOWN, NY - March 1, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a [...]
Sanofi : Le CHMP recommande l'approbation de l'indication de Dupixent® (dupilumab) dans l'asthme
01/03/2019
Le CHMP recommande l'approbation de l'indication de Dupixent ® (dupilumab) dans l'asthme Paris et Tarrytown (New York) - Le 1 er mars 2019 - Le Comité des médicaments à usage humain (CHMP, Committee for Medicinal [...]
Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
01/03/2019
– Fourth Quarter Andexxa ® Revenues of $14.0 Million; Third Consecutive Quarter of Strong Revenues – – Received Positive CHMP Opinion on Ondexxya™; European Commission Decision Anticipated in Early May – – Signed $125 [...]
Portola Pharmaceuticals Enters into $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management
01/03/2019
Agreement Provides Financial Flexibility for the Ongoing Commercialization of Andexxa® and Launch Preparations in Europe SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® ( [...]
Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes
01/03/2019
CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes PARIS and THE WOODLANDS, TX - March 1, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use ( [...]
Sanofi : Le CHMP recommande ZynquistaTM (sotagliflozine) pour le traitement du diabète de type 1 chez l'adulte
01/03/2019
Le CHMP recommande ZynquistaTM (sotagliflozine) pour le traitement du diabète de type 1 chez l'adulte Paris et The Woodlands (Texas) - Le 1 er mars 2019 - Le Comité des médicaments à usage humain (CHMP, Committee for [...]
Celldex to Report Full Year 2018 Business/Financial Results and Host Corporate Update Call
01/03/2019
HAMPTON, N.J., March 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2018 financial results on Thursday, March 7, 2019 after the U.S. financial markets [...]
Krystal Biotech to Present at the Cowen and Company 39th Annual Health Care Conference
01/03/2019
PITTSBURGH, March 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin [...]
Zealand Pharma to attend Credit Suisse and BioCapital Healthcare Conferences
01/03/2019
Press release – No. 04 / 2019 Zealand Pharma to attend Credit Suisse and BioCapital Healthcare Conferences Copenhagen, March 1, 2019 – Adam Steensberg, Interim Chief Executive Officer, will attend the Credit Suisse 2019 [...]
Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
01/03/2019
BOSTON, March 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]
Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA
01/03/2019
CRANBURY, N.J., March 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today the submission of its Investigational New Drug (IND) application with the U.S. Food and Drug [...]
Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019
01/03/2019
-- Orally administered PRN2246 achieved full BTK occupancy in peripheral blood -- -- PRN2246 exhibited blood-brain barrier permeability and CNS exposure -- -- Sanofi to lead Phase 2 development for people with Multiple [...]
Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
01/03/2019
ROCKVILLE, Md., March 01, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers [...]
Wellness Matrix Group To Initiate State-of-the-Art DNA Program
01/03/2019
LOS ANGELES, March 01, 2019 (GLOBE NEWSWIRE) -- Wellness Matrix Group, Inc. ( WMGR ), a technologically advanced Company in the Virtual Reality Artificial Intelligence health care model space, released details today on [...]
Bionano Genomics Launches New Capabilities of the Saphyr System to Significantly Increase Its Cost Effectiveness, Speed and Ease of Use for Whole Human Genome Structural Variation Analysis and Digital Cytogenetics
01/03/2019
The Saphyr platform is being used to drive the emergence of digital cytogenetics – a streamlined, comprehensive and cost-effective approach to modernize the clinical detection of structural variations which are at the [...]
Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis
01/03/2019
Three poster presentations from Phase 3 glycopyrronium tosylate clinical program address clinically relevant questions impacting people living with primary axillary hyperhidrosis New analysis from ATMOS-1 and ATMOS-2 [...]

Pages